The fountain of eternal youth could come in technological form thanks to $100 million investment in a life sciences company. Juvenescence is working with drug developers and AI experts to create treatments and technologies to treat age-related diseases and to increase human longevity. The firm, set up by London City of London entrepreneur Michael Spencer, announced a total investment of $10 million from its founders. A further $10 million each will come from four cornerstone investors, including Grok Ventures, Mike Cannon-Brookes and Mr Spencer's private investment company. This brings the total to $165 Million that Juvenescence has raised in 18 months.

The new collaboration is an indication of research into aging biomarkers together with the interventions discovered over the past five years is advancing. The collaboration is through the startup Napa Therapeutics, Ltd. Napa is to develop drugs against a novel aging-related target, as Business Insider reports. In terms of what each company will offer, the Buck Institute is one of the primary research centers focused on research into aging and the elimination of age-related disease. Insilico Medicine is an artificial intelligence pioneer, which is looking at on a range of factors associated with aging.

Sensyne Health, a London-based healthcare artificial intelligence (AI) company founded by biotech entrepreneur Paul Drayson, recently launched an initial public offering (IPO) on the London AIM market. Drayson's plan is to raise $78 million. It's just one of many companies that are exploiting advances in computing, data science and AI to help identify and develop potential new drugs. Drayson was formerly the UK's Minister of Science in the Department for Business, Innovation and Skills until May 2010, and before that, Minister of State for Strategic Defence Acquisition Reform at the Ministry of Defence. Drayson co-founded vaccine maker PowderJect Pharmaceuticals in 1993 and sold it in 2003 to Chiron for 524 million pounds.

The longevity and biotechnology industries are focusing on aging in a big way, and it's beginning to show. The fields of Artificial Intelligence (AI) and regenerative medicine are putting their money on combating aging and age-related diseases, and the benefits are likely to be immense. While biotechnology and AI are relatively new concepts, the announcements of funding and collaboration yesterday by and between three companies are bringing those concepts that much closer to the forefront of medicine. Insilico Medicine, a Baltimore-based next-generation AI company specializing in the application of deep learning for target identification, drug discovery and aging research, yesterday announced a collaboration agreement with WuXi AppTec, a leading global contract research outsourcing provider based in Shanghai, China, serving the pharmaceutical, biotech, and medical device industries. "It's a big step not only for Insilico Medicine but for AI and the pharmaceutical industries," said Alex Zhavoronkov, PhD, CEO of Insilico Medicine, Inc.

The longevity and biotechnology industries are focusing on aging in a big way, and it's beginning to show. The fields of Artificial Intelligence (AI) and regenerative medicine are putting their money on combating aging and age-related diseases, and the benefits are likely to be immense. While biotechnology and AI are relatively new concepts, the announcements of funding and collaboration yesterday by and between three companies are bringing those concepts that much closer to the forefront of medicine. Insilico Medicine, a Baltimore-based next-generation AI company specializing in the application of deep learning for target identification, drug discovery and aging research, yesterday announced a collaboration agreement with WuXi AppTec, a leading global contract research outsourcing provider based in Shanghai, China, serving the pharmaceutical, biotech, and medical device industries. "It's a big step not only for Insilico Medicine but for AI and the pharmaceutical industries," said Alex Zhavoronkov, PhD, CEO of Insilico Medicine, Inc.

The longevity and biotechnology industries are focusing on aging in a big way, and it's beginning to show. The fields of Artificial Intelligence (AI) and regenerative medicine are putting their money on combating aging and age-related diseases, and the benefits are likely to be immense. While biotechnology and AI are relatively new concepts, the announcements of funding and collaboration yesterday by and between three companies are bringing those concepts that much closer to the forefront of medicine. Insilico Medicine, a Baltimore-based next-generation AI company specializing in the application of deep learning for target identification, drug discovery and aging research, yesterday announced a collaboration agreement with WuXi AppTec, a leading global contract research outsourcing provider based in Shanghai, China, serving the pharmaceutical, biotech, and medical device industries. "It's a big step not only for Insilico Medicine but for AI and the pharmaceutical industries," said Alex Zhavoronkov, PhD, CEO of Insilico Medicine, Inc.

IMAGE: The first drug-candidate compounds targeting age-related diseases discovered using AI are licensed for development. Jan.6, 2018, Baltimore, Maryland- Insilico Medicine, Inc. ("Insilico"), a Baltimore-based next-generation artificial intelligence (AI) company specializing in the application of deep learning for drug discovery, announces that Juvenescence.AI, its joint venture with Juvenescence Limited ("Juvenescence"), has licensed its first compound family for clinical development. This is one of five compound families that Juvenescence.AI is able to license each year under its license agreement with Insilico. "The selection of our first compound family is a landmark event for Juvenescence, and a broader comment on the potential of AI to transform the drug discovery and development industry" commented Jim Mellon, Chairman of Juvenescence. This deal is a result of a deep collaboration between the senior drug developers at Juvenescence and AI experts at Insilico and signifies a new era in drug discovery where highly sophisticated AI finds viable drug candidates.